Mismatch repair deficiency predicts response of solid tumors to PD-1 blockadeDung T. Le, Luis A. Díaz, Jennifer N. Durham et al.|Science|2017Cited by 6.6k
Neoadjuvant PD-1 Blockade in Resectable Lung CancerPatrick M. Forde, Drew M. Pardoll, Haidan Guo et al.|New England Journal of Medicine|2018Cited by 2.1k
Evolution of Neoantigen Landscape during Immune Checkpoint Blockade in Non–Small Cell Lung CancerValsamo Anagnostou, Victor E. Velculescu, Kellie N. Smith et al.|Cancer Discovery|2016Cited by 897
Pathologic features of response to neoadjuvant anti-PD-1 in resected non-small-cell lung carcinoma: a proposal for quantitative immune-related pathologic response criteria (irPRC)Tricia R. Cottrell, Janis M. Taube, Elizabeth D. Thompson et al.|Annals of Oncology|2018Cited by 588
Transcriptional programs of neoantigen-specific TIL in anti-PD-1-treated lung cancersJustina X. Caushi, Taha Merghoub, Kellie N. Smith et al.|Nature|2021Cited by 546